OBJECTIVES: In Brazil, the injectable octreotide is present in the National List of Essential Medicines (RENAME 2014). It is indicated to the treatment of severe diarrhea and flushing caused by certain types of cancer. It is also used to treat acromegaly in certain patients. However, its use has also been identified in the treatment of pancreatic cancer. This study aimed to evaluate the therapeutic indication of octreotide in various pharmaceutical forms, in order to present response to this new inclusion to RENAME 2016. METHODS: The research was carried out in the specialized literature on February 15, 2015, on the Best Practice (BMJ), Dynamed and UpToDate databases, being used the DeCS and MeSH indexed terms: "Pancreatic Neoplasms" and "Octreotide". Details on the evidence were identified on the use of 0.1mg, 10mg, 20mg and 30mg/mL injectable octreotide for the treatment of the cited neoplasia. RESULTS:  No evidence was located on BMJ and UpToDate databases. It was located on Dynamed database that the use of 100μg subcutaneous octreotide three times a day during 7 days is recommended for patients undergoing pancreas surgery. On Micromedex database it was found the use of octreotide and alpha interferon are effective in the treatment of advanced metastatic disease in patients unresponsive to the single use of octreotide. The recommended dosage of octreotide associated with interferon alpha is 200μg, 3 times a day. CONCLUSIONS:  There is evidence on the use of octreotide to treat patients with pancreas cancer. Therefore, it is recommended to include its 0.1mg, 10mg, 20mg and 30 mg/mL injected form in RENAME 2016, for the indication evaluated.